The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals’ European marketing authorization for EchoGen, Sonus’ ultrasound contrast agent. The EMEA approval enables Sonus to begin
The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals European marketing authorization for EchoGen, Sonus ultrasound contrast agent. The EMEA approval enables Sonus to begin production of EchoGen in Europe. The Bothell, WA-based company is currently in discussions with potential marketing partners in Europe and expects to have several of these relationships in place early this year. In November, Sonus took back exclusive marketing rights to EchoGen in Europe, Latin America, Canada, the Middle East, and certain Asia Pacific countries from its previous marketing partner outside the U.S., Abbott International (SCAN 11/27/99).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.